NLS Pharmaceutics Future Growth
Future criteria checks 3/6
NLS Pharmaceutics se prevé un crecimiento anual de los beneficios y los ingresos de 59.6% y 79.5%, respectivamente, mientras que el BPA aumentará de grow a 58.5%.
Key information
55.6%
Earnings growth rate
55.9%
EPS growth rate
Pharmaceuticals earnings growth | 21.9% |
Revenue growth rate | 59.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 02 Feb 2024 |
Recent future growth updates
Recent updates
NLS Pharmaceutics gets delisting determination letter from Nasdaq
Oct 05NLS Pharma falls 17% despite positive Phase 2 data for narcolepsy candidate
Sep 27NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders
Jul 28Here's Why We're A Bit Worried About NLS Pharmaceutics' (NASDAQ:NLSP) Cash Burn Situation
Mar 04Companies Like NLS Pharmaceutics (NASDAQ:NLSP) Could Be Quite Risky
Nov 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 133 | 70 | N/A | N/A | 1 |
12/31/2025 | N/A | -27 | N/A | N/A | 1 |
12/31/2024 | N/A | -24 | N/A | N/A | 1 |
12/31/2023 | N/A | -20 | N/A | N/A | 1 |
6/30/2023 | N/A | -15 | -14 | -14 | N/A |
3/31/2023 | N/A | -16 | -14 | -14 | N/A |
12/31/2022 | N/A | -16 | -14 | -14 | N/A |
9/30/2022 | N/A | -16 | -13 | -13 | N/A |
6/30/2022 | N/A | -16 | -13 | -13 | N/A |
3/31/2022 | N/A | -14 | -14 | -14 | N/A |
12/31/2021 | N/A | -12 | -15 | -15 | N/A |
9/30/2021 | N/A | -9 | N/A | N/A | N/A |
6/30/2021 | N/A | -6 | -10 | -10 | N/A |
3/31/2021 | N/A | -5 | -5 | -5 | N/A |
12/31/2020 | N/A | -3 | -1 | -1 | N/A |
9/30/2020 | N/A | -3 | N/A | N/A | N/A |
6/30/2020 | N/A | -3 | -1 | -1 | N/A |
3/31/2020 | N/A | -4 | -1 | -1 | N/A |
12/31/2019 | N/A | -5 | 0 | 0 | N/A |
9/30/2019 | N/A | -6 | N/A | N/A | N/A |
6/30/2019 | N/A | -6 | 0 | 0 | N/A |
3/31/2019 | N/A | -6 | -2 | -2 | N/A |
12/31/2018 | N/A | -5 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: NLSP se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.2%).
Beneficios frente mercado: NLSP se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: NLSP se espera que sea rentable en los próximos 3 años.
Ingresos vs. Mercado: NLSP no tendrá ingresos el año que viene.
Ingresos de alto crecimiento: NLSP no tendrá ingresos el año que viene.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de NLSP se prevé elevada dentro de 3 años.